<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04414475</url>
  </required_header>
  <id_info>
    <org_study_id>XPORT-MM-028</org_study_id>
    <nct_id>NCT04414475</nct_id>
  </id_info>
  <brief_title>A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients With Triple-class Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, antitumor activity, safety and
      tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory
      multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with
      triple-class refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>From the date of randomization up to death (approximately 14 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the date of randomization to first disease progression or death (approximately 14 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>From the date of randomization up to death (approximately 14 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From the date of randomization up to death (approximately 14 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From the date of randomization to first disease progression or death (approximately 14 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the date of randomization up to death (approximately 14 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Treatment (TTNT)</measure>
    <time_frame>From the date of first dose up to death (approximately 14 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AE)</measure>
    <time_frame>From start of study drug administration up to follow-up (approximately 3 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Multiple Myeloma, Refractory</condition>
  <arm_group>
    <arm_group_label>Selinexor + Low-dose Dexamethasone (Sd-40 BIW)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive fixed dose of 40 milligram (mg) of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet twice weekly (BIW) on Days 1, 3, 8, 10, 15, 17, 22, and 24 of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selinexor + Low-dose Dexamethasone (Sd-100 QW)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive fixed dose of 100 mg of Selinexor oral tablet followed by 40 mg of low-dose Dexamethasone oral tablet once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle. (Dexamethasone may be given as 20 mg on days 1 and 2 of each week).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selinexor + Low-dose Dexamethasone (Sd-80 BIW)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive fixed dose of 80 mg of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet BIW on Days 1, 3, 8, 10,15, 17, 22, and 24 of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selinexor + Bortezomib + Dexamethasone (SVd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive fixed dose of 100 mg of Selinexor oral tablet on Days 1, 8, 15, 22, and 29 followed by 1.3 milligram per square-meter (mg/m^2) of Bortezomib subcutaneous (SC) injection on Days 1, 8, 15, and 22 and followed by 40 mg of low-dose Dexamethasone oral tablet on Days 1, 8, 15, 22, and 29 of each 35-day cycle (Dexamethasone dose may be split to 20 mg on days 1 and 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Participants will receive Selinexor oral tablets.</description>
    <arm_group_label>Selinexor + Bortezomib + Dexamethasone (SVd)</arm_group_label>
    <arm_group_label>Selinexor + Low-dose Dexamethasone (Sd-100 QW)</arm_group_label>
    <arm_group_label>Selinexor + Low-dose Dexamethasone (Sd-40 BIW)</arm_group_label>
    <arm_group_label>Selinexor + Low-dose Dexamethasone (Sd-80 BIW)</arm_group_label>
    <other_name>KPT-330</other_name>
    <other_name>XPOVIO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Participants will receive Dexamethasone oral tablets.</description>
    <arm_group_label>Selinexor + Bortezomib + Dexamethasone (SVd)</arm_group_label>
    <arm_group_label>Selinexor + Low-dose Dexamethasone (Sd-100 QW)</arm_group_label>
    <arm_group_label>Selinexor + Low-dose Dexamethasone (Sd-40 BIW)</arm_group_label>
    <arm_group_label>Selinexor + Low-dose Dexamethasone (Sd-80 BIW)</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Participants will receive Bortezomib SC injection.</description>
    <arm_group_label>Selinexor + Bortezomib + Dexamethasone (SVd)</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to (≥)18 years at the time of signing informed consent.

          -  Written informed consent in accordance with federal, local, and institutional
             guidelines.

          -  Measurable MM based on IMWG guidelines as defined by at least one of the following:

               1. Serum M-protein ≥ 0.5 gram per deciliter (g/dL) by serum protein electrophoresis
                  (SPEP) or, for Immunoglobulin (Ig) A myeloma, by quantitative IgA.

               2. Urinary M-protein excretion ≥ 200 mg/24 hours.

               3. Free light chain (FLC) ≥ 100 milligram per liter (mg/L), provided that the FLC
                  ratio is abnormal.

          -  Only for arms Sd-40 BIW, Sd-100 QW and Sd-80 BIW: Participants must have relapsed or
             refractory multiple myeloma (RRMM) and have previously received at least 4 anti-MM
             prior therapies and have MM that is refractory to previous treatment with at least 2
             proteasome inhibitors (PIs), at least 2 immunomodulatory agent (IMiDs), and 1
             anti-cluster of differentiation (CD38) monoclonal antibody. Refractory is defined as
             lesser than or equal to (≤) 25 percent (%) response to therapy, or progression during
             therapy or progression within 60 days after completion of therapy.

          -  Only for arm SVd: Participants must have previously received 1 to 5 anti-MM prior
             therapies and have MM that is refractory to previous treatment with at least 1 PI, at
             least 1 IMiD, and 1 anti- CD38 monoclonal antibody.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

          -  Female participants of childbearing potential must agree to use dual methods of
             contraception and have a negative serum pregnancy test at screening, and male
             participants must use an effective barrier method of contraception if sexually active
             with a female of childbearing potential. For both male and female participants,
             effective methods of contraception must be used throughout the study and for 7 months
             for female and 4 months for male following the discontinuation of study treatment.

          -  Participants agrees to provide bone marrow aspirate to be used for genetic testing of
             participants agrees to provide bone marrow aspirate to be used for genetic testing of
             deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).

        Exclusion Criteria:

          -  Active plasma cell leukemia.

          -  Documented systemic amyloid light chain amyloidosis.

          -  Active central nervous system MM.

          -  Only for SVd arm: Greater than Grade 2 peripheral neuropathy or Grade ≥ 2 peripheral
             neuropathy with pain at baseline, regardless of whether or not the participant is
             currently receiving medication.

          -  Radiation, chemotherapy, immunotherapy, or any other anticancer therapy (including
             investigational therapies) ≤ 2 weeks prior to Cycle 1 Day 1 (C1D1). (Steroids are
             permitted up to 1 pulse of 40 mg per day for 4 days in the 2 weeks prior to C1D1).

          -  Active graft vs. host disease (after allogeneic stem cell transplantation) at C1D1.

          -  Ongoing clinically significant non-hematological toxicities from prior treatments that
             are Grade greater than (&gt;) 2 at C1D1.

          -  Inadequate hepatic function defined as total bilirubin ≥ 2x upper limit of normal
             (ULN) (≥ 3x ULN for participants with Gilbert's syndrome), aspartate transaminase
             (AST) ≥ 2.5x ULN, and alanine transaminase (ALT) ≥ 2.5x ULN.

          -  Inadequate renal function defined as estimated creatinine clearance of lesser than (&lt;)
             20 milliliter per minute (mL/min), calculated using the formula of Cockroft and Gault.

          -  Inadequate hematopoietic function defined as the following:

               1. Absolute neutrophil count (ANC) &lt; 1000/cubic millimeter (mm3)

               2. Platelet count &lt; 75,000/mm3

               3. Hemoglobin (Hb) level &lt; 8.5 g/dL

          -  Life expectancy of &lt; 4 months, based on the opinion of the Investigator.

          -  Major surgery within 4 weeks prior to C1D1.

          -  Uncontrolled active infection requiring parenteral antibiotics, antivirals, or
             antifungals within 1 week prior to first dose.

          -  Active gastrointestinal dysfunction interfering with the ability to swallow tablets,
             or any gastrointestinal dysfunction that could interfere with absorption of the study
             treatment.

          -  Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C
             virus RNA or hepatitis B virus surface antigen.

          -  Receipt of red blood cells (RBC) transfusions within 2 weeks of C1D1.

          -  Receipt of platelet transfusion within 1 week of C1D1.

          -  Receipt of the following blood growth factors within 2 weeks prior to C1D1:
             Granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating
             factor, erythropoietin, or megakaryocyte growth factor.

          -  Female participants who are pregnant or lactating.

          -  Known intolerance, hypersensitivity, or contraindication to glucocorticoid therapy at
             C1D1.

          -  Concurrent therapy with approved or investigational anticancer therapeutic including
             topical therapies.

          -  Prior exposure to a SINE compound, including selinexor.

          -  Serious, active psychiatric or active medical conditions which, in the opinion of the
             Investigator or the Sponsor, could interfere with the participation in the study.

          -  Contraindication to any of the required concomitant drugs or supportive treatments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jatin Shah Chief Medical Officer, MD</last_name>
    <phone>(617) 658-0600</phone>
    <email>jshah@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham Chief Scientific Officer, PhD</last_name>
    <phone>(617) 658-0600</phone>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <state>Achaia</state>
        <zip>2654</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prof. Anargyros Symeonidis</last_name>
      <phone>+30 6944960012</phone>
      <email>argiris.symeonidis@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Prof. Anargyros Symeonidis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;ALEXANDRA&quot;</name>
      <address>
        <city>Attiki</city>
        <state>Athens</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Maria Gavriatopoulou</last_name>
      <phone>+30 6934137080</phone>
      <email>mariagabria@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Prof. Maria Gavriatopoulou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Evaggelismos&quot;</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Sosana Delimpasi</last_name>
      <phone>(+30697)7204193</phone>
      <email>sodeli@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Sosana Delimpasi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Theageneion Cancer Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54007</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eirini Katoudritou</last_name>
      <phone>+30 6974872869</phone>
      <email>eirinikatodritou@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eirini Katoudritou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evgeni Chubar</last_name>
      <phone>972 52 7828012</phone>
      <email>Chubar_ev@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Evgeni Chubar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assuta Ashdod Medical Center</name>
      <address>
        <city>Ashdod</city>
        <zip>7747629</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Merav Leiba</last_name>
      <phone>972 58 666 9161</phone>
      <email>meravlei@assuta.co.il</email>
    </contact>
    <investigator>
      <last_name>Merav Leiba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Miri Zekster</last_name>
      <phone>050-589-3962</phone>
      <email>MIRISP2@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Dr. Miri Zekster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bnai-Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3108</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tamar Tadmor</last_name>
      <phone>972506268114</phone>
      <email>Tamar.tadmor@b-Zion.org.il</email>
    </contact>
    <investigator>
      <last_name>Tamar Tadmor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noa Lavi</last_name>
      <phone>972 50 206 1332</phone>
      <email>n_lavi@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Noa Lavi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chezi Ganzel</last_name>
      <phone>972-53-3342046</phone>
      <email>ganzelc@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Chezi Ganzel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Gatt</last_name>
      <phone>972-505172333</phone>
      <email>rmoshg@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Moshe Gatt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center (Beilinson Hospital)</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amos Cohen</last_name>
      <phone>972-50-565-1033</phone>
      <email>amosc@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Amos Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center at Tel HaShomer</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hila Magen</last_name>
      <phone>972 50 406 5432</phone>
      <email>hila.magen@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Hila Magen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yael Cohen</last_name>
      <phone>972 52 662 2575</phone>
      <email>yaelcoh@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Yael Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 2, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Selinexor</keyword>
  <keyword>Penta-refractory Multiple Myeloma</keyword>
  <keyword>Triple-class Refractory Multiple Myeloma</keyword>
  <keyword>KPT-330</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

